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Abstract
Background: As a cellular membrane triggering receptor, CD226 is involved in the NK cell- or
CTL-mediated lysis of tumor cells of different origin, including freshly isolated tumor cells and
tumor cell lines. Here, we evaluated soluble CD226 (sCD226) levels in sera, and membrane CD226
(mCD226) expression on peripheral blood mononuclear cells (PBMC) from cancer patients as well
as normal subjects, and demonstrated the possible function and origin of the altered sCD226,
which may provide useful information for understanding the mechanisms of tumor escape and for
immunodiagnosis and immunotherapy.
Results: Soluble CD226 levels in serum samples from cancer patients were significantly higher than
those in healthy individuals (P < 0.001), while cancer patients exhibited lower PBMC mCD226
expression than healthy individuals (P < 0.001). CD226-Fc fusion protein could significantly inhibit
the cytotoxicity of NK cells against K562 cells in a dose-dependent manner. Furthermore, three
kinds of protease inhibitors could notably increase mCD226 expression on PMA-stimulated
PBMCs and Jurkat cells with a decrease in the sCD226 level in the cell culture supernatant.
Conclusion: These findings suggest that sCD226 might be shed from cell membranes by certain
proteases, and, further, sCD226 may be used as a predictor for monitoring cancer, and more
important, a possible immunotherapy target, which may be useful in clinical application.
Background
CD226, also named platelet and T cell antigen 1 (PTA1)
or DNAX accessory molecule-1 (DNAM-1), is a trans-
membrane glycoprotein belonging to the immunoglobu-
lin superfamily. The CD226 molecule is mainly expressed
on NK cells, T cells, NK T cells, and platelets, and is
involved in cytotoxicity and cytokine secretion of T cells
and NK cells and in platelet aggregation and activation [1-
4]. It is highly conserved among human, gibbon, monkey,
and mouse, suggesting this molecule may have important
biological functions [5]. Recently, CD226 has been iden-
tified as a receptor for CD112 and CD155 [6], and ligation
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(LFA-1) with their respective ligands cooperates in trigger-
ing cytotoxicity and cytokine secretion by T and NK cells
[7].
Recently, more attention has been paid to a putative role
for CD226 in tumor development. The specific interac-
tion between CD226 (on NK cells) and CD155 or CD112
(on tumor cells) plays an important role in the NK-medi-
ated lysis of tumor cells [8-11]. Based on that, CD226 is
thought to be one of the major activating NK receptors
[12,13] and involved in tumor immunosurveillance [14].
Moreover, the abnormal expression of CD226 and its lig-
ands in some tumors may be involved in the mechanisms
of tumor escape, invasion, and migration [15,16].
Although soluble CD155 has been detected in human
serum and cerebrospinal fluid [17] and is anticipated to
be one of the mechanisms of tumor immune escape [14],
there has been no report on soluble CD226 (sCD226) or
the levels of membrane CD226 (mCD226) and their rela-
tionship in tumors. Here, based on the mAbs and ELISA
system established by our laboratory [18], we describe
increased sCD226 levels in sera and lower mCD226
expression on PBMC from cancer patients compared with
those of normal subjects, and demonstrate the possible
function and origin of the increased sCD226. These find-
ings may provide useful information for understanding
the mechanisms of tumor escape and for immunodiagno-
sis.
Results and Discussion
Elevated sCD226 levels in sera and reduced mCD226 
expression on PBMC in cancer patients
Using the Sandwich ELISA, we found that the concentra-
tion of sCD226 was significantly higher in serum from
cancer patients than in serum from normal subjects: the
ranges of serum sCD226 being 0.1–23 (median 6.3) ng/
mL in normal subjects and 0.2–60 (median 11.5) ng/mL
in cancer patients (P < 0.001, Fig. 1A). This increase in
serum sCD226 was evident in most of the tumor types we
tested except liver cancer (Fig. 1B), a finding consistent
with the fact that all of the tumor types shown here have
been identified to express CD155 and/or CD112
[8,17,19-22]. It is known that many membrane molecules
can be shed from the cell surface and released into the cir-
culation in soluble form in some pathological conditions
such as tumor [23-26]. To investigate whether the
increased sCD226 in cancer patients might be shed from
the cell surface, we examined the mCD226 on PBMC from
both patients and normal subjects. Accordingly, it was
found that the expression of mCD226 by PBMC from can-
cer patients was lower than that from normal subjects,
with a statistically significant difference (P < 0.001, Fig.
1C). The reduction of mCD226 expression on PBMC from
cancer patients was not surprising, since it had been
reported that CD226 was reduced on CD56dim NK cells
from myeloma patients with active disease compared with
patients in remission and healthy controls [11].
Inhibitory effect of CD226-Fc fusion protein on the 
cytotoxicity of normal PBMC against K562 cells
It has been well accepted that the cytotoxicity mediated by
NK cells and effector T cells is one of the major mecha-
nisms of immune surveillance against tumor cells. How-
ever, malignant cells often have developed strategies that
counteract immune surveillance of the hosts, such as
secreting soluble activating killing receptors and/or their
ligands to avoid or reduce this kind of killing [27-30]. To
investigate the possible effect of sCD226 on this cytolytic
function against malignant cells, and whether sCD226
could be one of the tumor escape strategies, a CD226-Fc
fusion protein was used to mimic the function of sCD226
in vitro. NK cytolytic activity was then measured by co-
incubation of normal PBMC with the NK-sensitive K562
cell line, which expresses both CD226 ligands (Fig. 2A), in
a standard 51Cr-release assay, with or without CD226-Fc
fusion protein. As expected, CD226-Fc fusion protein
could inhibit the cytotoxicity of NK cells against K562
cells in a dose-dependent manner and the inhibition was
of statistic significance when the concentration was 250,
500, and 1000 ng/mL (P < 0.05, Fig. 2B and Fig. 2C).
Although the effective concentration of CD226-Fc
required for inhibition in vitro was 10–20 fold greater than
that observed in patients' sera, the situation in vivo is likely
to be quite different. First, it is known that many different
inhibitory molecules are shed by tumor cells, therefore
sCD226 is likely to constitute only one of a number of
molecules that each contribute to inhibition; second, nat-
ural sCD226 in vivo may contain structural differences
from the CD226-Fc fusion protein, which was expressed
and purified artificially and in a form of homodimer
linked by human Ig Fc fragment, and these may yield a
higher affinity of binding to CD155 and/or CD112. It can
be speculated, therefore, that the increased sCD226 in
sera from tumor patients might play a role in blocking or
inhibiting the binding of mCD226 to its ligands on the
tumor cell, thereby inhibiting tumor cell lysis.
Regulation of sCD226 and mCD226 by protease inhibitors
Having observed the increased serum sCD226 in cancer
patients and presenting a possible role for the increased
sCD226, we then sought to determine the origin of the
sCD226. Based on the fact that many transmembrane
molecules are cleaved by certain proteases and shed into
the circulation, and that several kinds of proteases can be
induced in vitro by treatment with PMA [31-33], we inves-
tigated the effect on the regulation of sCD226 and
mCD226 of PMA-stimulated normal PBMC and Jurkat
cells by the treatment with 15 different protease inhibitors
(data not shown). As shown in Fig. 3A and 3B, three of thePage 2 of 8
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protease inhibitor; AEBSF: a serine protease inhibitor; N-
Ethylmaleimide: a cysteine protease inhibitor) signifi-
cantly decreased sCD226 level and increased mCD226
expression of the cultured cells treated with PMA. These
data indicate that CD226 can be shed from the cell surface
by proteolysis and released into the circulation in soluble
form, and this shedding might involve more than one
protease. Similarly, many other transmembrane receptors
and cell adhesion molecules, can be shed from the cell
surface by proteolysis and released into the circulation in
soluble form, and such shedding can involve more than
one protease [34]. Our finding that this process likely
occurs in a number of cancers is perhaps not surprising
since it is known that in these conditions many proteases
are up-regulated [35].
Characterization of the sCD226
In order to exclude the possibility that the sCD226 was, in
fact, intact mCD226 derived from dead cells, we charac-
terized the molecular weight of sCD226 both in sera sam-
ples from healthy donors and cancer patients and in the
culture supernatants from normal PBMC and Jurkat cells
treated with PMA for 24 h. All the four samples were aliq-
uoted into 3 tubes: one was precipitated with normal
mouse IgG-Sepharose 4B and probed with an anti-CD226
mAb FMU4 [18], one was precipitated with LeoA1-Sepha-
rose 4B and probed with anti-SED (staphylococcal enter-
Sera sCD226 level and PBMC mCD226 expression of cancer patients and normal subjectsFigure 1
Sera sCD226 level and PBMC mCD226 expression of cancer patients and normal subjects. (A) Comparison of 
sCD226 levels in sera of cancer patients and healthy individuals. Plots (generated using SPSS) show the range of data values 
obtained. Two hundred and fifty-nine cancer patients (135 male and 124 female, ages 25–65 y) were compared with 129 
healthy individuals (69 male and 60 female, ages 25–65 y). (B) Comparison of sCD226 levels in sera of individual patient groups 
and control group. Data of 49 patients with other kinds of tumors are not shown here due to the large number of tumor types 
and small sample number of each type. (C) Comparison of positive percentage of mCD226 on PBMC from cancer patients (10 
male and 4 female, ages 25–45 y) and healthy individuals (8 male and 4 female, ages 25–40 y). Top and bottom whiskers, values of 
the top and bottom 25% of the cases, respectively; boxed area, inter-quartile range and the significant P values between groups; 
horizontal black line, median value; stars and circles, extreme and outlying values, respectively (as defined by SPSS).Page 3 of 8
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LeoA1-Sepharose 4B and probed with FMU4. As shown in
Fig. 4, protein bands were only observed when the sam-
ples were precipitated with LeoA1-Sepharose 4B and
probed with FMU4. As expected, a band with molecular
weight of ~50 kDa, coincident with the extracellular
domain of CD226 molecule, was found in all the four
kinds of sera and supernatant samples. Interestingly,
another weaker band, with molecular massed of ~45 kDa,
was observed in sera samples, but not in supernatant sam-
ples. Based on these findings, we speculate a reasonable
explanation for the smaller molecule might be the variety
of proteases in vivo, leading to the cleavage of sCD226
from different sites of the intact molecule. However, the
possibility of heterogeneous glycosylation of sCD226 in
vivo cannot be excluded.
Conclusion
We have revealed that the sCD226 levels in sera of cancer
patients is significantly enhanced compared with that in
normal subjects, while there is a concomitant reduction in
mCD226 expression on PBMC isolated from cancer
patients. CD226-Fc fusion protein can notably inhibit the
cytotoxicity of normal PBMC against K562 cells, indicat-
ing that the increased sCD226 might be one of the
immune escape strategies used by tumor cells. Three pro-
tease inhibitors can decrease sCD226 level and increase
mCD226 expression of PMA-stimulated PBMC and Jurkat
cells, indicating that the increased serum sCD226 in can-
cer patients might be shed from the cell surface by several
proteases, which are often up-regulated when tumor
occurs. These findings suggest that sCD226 might be used
as a predictor for monitoring cancer, and more important,
a possible immunotherapy target, which may be useful in
clinical application.
Effect of CD226-Fc fusion protein on cytotoxicity of normal PBMC against K562 cellsFigure 2
Effect of CD226-Fc fusion protein on cytotoxicity of normal PBMC against K562 cells. (A) Expression of CD155 
and CD112 by K562 cells. Solid line, CD155 and CD112 staining; black areas, isotype controls. (B) Inhibitory effect of CD226-Fc 
fusion protein (1000 ng/mL) on cytotoxicity of NK cells against K562 cells. Medium/human Ig (1000 ng/mL) and anti-CD155/
CD112 mAbs were used as negative and positive control, respectively. (C) Inhibition of CD226-Fc on cytotoxicity of NK cells 
against K562 cells in a dose-dependent manner (*, P < 0.05 vs. human Ig of corresponding concentration). The data were the 
mean ± SD of four wells for each group. Representative experiments are shown (n = 3).Page 4 of 8
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Patients' and control sera
Samples of patients' sera were obtained from 259 patients
with various kinds of tumors, before treatment, within 1
week after entrance to Xijing Hospital, the Fourth Military
Medical University. The series included a total of 13
esophageal carcinoma (7 male and 6 female), 45 gastric
carcinoma (25 male and 20 female), 24 colorectal carci-
noma (11 male and 13 female), 23 liver cancer (13 male
and 10 female), 16 breast cancer (female), 15 cervix/ovar-
ian/endometrial cancer (female), 46 lung cancer (28 male
and 18 female), 28 leukemia/lymphoma (14 male and 14
female), and 49 others (including tumor in central nerv-
ous system, in kidney, in bladder, in parotid gland, in thy-
roid gland, in submaxilary gland, in suprarenal gland, in
prostate gland, cholangiocarcinoma, melanoma,
nasopharyngeal carcinoma, laryngocarcinoma, soft tissue
sarcoma, and osteogenic sarcoma). Normal sera were iso-
lated from 129 healthy volunteers (69 male and 60
female). Both the patients and the volunteers were 25–65
years old. They had no chemotherapy and had no signifi-
cant signs or symptoms of microbial infection at the time
of entrance. This study was approved by the institutional
review board of the University and all individuals pro-
vided written and/or oral informed consent. The sera were
stored at -20°C until use.
Sandwich ELISA
100 μL of the anti-CD226 mAb, LeoA1 [1] (2.5 mg/L in
0.05 M sodium carbonate buffer, pH9.5) was added to
each well of an ELISA plate (Nunc, Roskilde, Denmark)
and incubated overnight at 4°C. After three washes, serum
samples or standard CD226 serially diluted with PBS con-
taining 1% BSA and 0.1% (v/v) Tween-20 were added to
the wells and incubated for 1 h at 37°C. After extensive
washing with PBS containing 0.1% (v/v) Tween-20 (PBS/
Tween), the wells were reacted with another anti-CD226
mAb [18] which was conjugated with HRP and diluted in
PBS containing 3% PEG for 1 h at 37°C. Color develop-
ment was performed by adding 100 μL TMB (eBioscience,
CA, USA) for 10 min at 37°C and stopped by 2 M H2SO4.
The absorbance at 450 nm was determined with a micro-
plate reader (BioRad, CA, USA).
Flow cytometry analysis
PBMC were freshly isolated from peripheral blood of
healthy adults or cancer patients by Isopaque-Ficoll (Hao
Yang, Tianjin, China) gradient centrifugation and incu-
bated with LeoA1 or control IgG1 (BD BioSciences, CA,
USA) at 4°C for 30 min, followed by washing and incuba-
tion with FITC-labeled goat anti-mouse Ig (Dako, Glos-
trup, Denmark) at 4°C for 30 min and then analyzed on
a FACScan (BD BioSciences). Expression of CD155 and
CD112 on K562 cells were analyzed similarly.
Effect of protease inhibitors on sCD226 level and mCD226 expression of normal PBMS or Jurkat cellsFigure 3
Effect of protease inhibitors on sCD226 level and mCD226 expression of normal PBMS or Jurkat cells. (A) 
Reduced levels of sCD226 in supernatant of PMA-stimulated PBMC or Jurkat cells treated with or without 1 mM protease 
inhibitor (1–10-Phenanathroline, AEBSF, or N-Ethylmaleimide). The data were the mean ± SD of three wells for each group. (*, 
P < 0.05 vs. nil group). (B) Enhanced expression of mCD226 on PMA-stimulated PBMC or Jurkat cells treated with or without 
1 mM 1–10-Phenanathroline, AEBSF, or N-Ethylmaleimide. Solid line, without protease inhibitors; grey areas, with protease 
inhibitors; black areas, isotype controls. Representative experiments are shown (n = 3).Page 5 of 8
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NK cytolytic activity was measured after co-incubation of
normal PBMC with the NK-sensitive K562 cell line by a
standard 51Cr-release assay. Briefly, K562 cells were
labelled with 51Cr (Amersham biosciences, NJ, USA, 100
μCi/106 cells) for 2 h at 37°C. After three washes, 51Cr-
labelled target cells were incubated with various concen-
trations of CD226-Fc fusion proteins, control protein
(human Ig), or anti-CD155/CD112 mAb for 30 min at
37°C. Meanwhile, freshly isolated PBMCs were incubated
with 10% of normal human serum or normal murine
serum for 30 min at 37°C. Then the target cells and effec-
tor cells were pooled together (1×104/well K562 and
1×105/well PBMC) and incubated for 4 h at 37°C. The
percentage of cytotoxicity was calculated as percentage
specific lysis, as follows:
Cell culture and stimulation
Freshly isolated normal PBMC or Jurkat cells were cul-
tured in RPMI 1640 (Hyclone, UT, USA) supplemented
with 10% FCS, 100 U/mL penicillin/streptomycin, 10
mM HEPES, and 50 μM β-mercaptoethanol at 37°C in 5%
CO2. The cells (1×106 cells/mL) were stimulated with
PMA (50 ng/mL, Sigma-Aldrich, MO, USA) for 6 h,
washed twice, and co-cultured with or without different
protease inhibitors (Sigma-Aldrich, INHIB-1 and
131377) for 6 h. Although the concentration of the 15
protease inhibitors was not all the same, the optimized
concentration for 3 effective protease inhibitors (1–10-
Phenanathroline, AEBSF, and N-Ethylmaleimide) was all
1 mM. Then sCD226 level in the supernatants was
detected by the ELISA mentioned above, and mCD226
expression on the cells was analyzed by flow cytometry.
Characterization of molecular weight of sCD226
Twelve ml of serum from cancer patients and healthy
adults, respectively, and 30 ml of culture supernatant
from normal PBMC and Jurkat cells treated with PMA (50
ng/mL) for 24 h were used to characterize the molecular
weight of sCD226 by immunoprecipitaion and Western
blot analysis. Briefly, LeoA1 or normal mouse IgG was
covalently coupled to CNBr-activated Sepharose 4B (GE
Healthcare, London, the United Kingdom) according to
the manufacturer's instructions. After preclearing, the sera
or supernatant samples were aliquoted and incubated
Percentage specific lysis experimental Cr release spon= −[( 51 taneous Cr release




(÷ − 51 100Cr release T)] .×
Characterization of molecular weight of sCD226Figure 4
Characterization of molecular weight of sCD226. Sera from healthy individuals (A) and cancer patients (B), or superna-
tant from PMA-activated PBMC (C) and PMA-activated Jurkat cells (D) were precipitated and detected as following: Lane 1, the 
samples were precipitated with normal mouse IgG-Sepharose 4B (negative control for immunoprecipitation) and detected with 
FMU4 (anti-CD226 mAb) in Western blot. There was no band because sCD226 could not be precipitated by normal mouse 
IgG-Sepharose 4B. Lane 2, the samples were precipitated with anti-CD226 mAb, LeoA1-Sepharose 4B and detected with anti-
SED (staphylococcal enterotoxin D) mAb (negative control for blotting reagent) in Western blot. There was still no band 
because the precipitated sCD226 could not be detected with anti-SED mAb in Western blot. Lane 3, the samples were precip-
itated with LeoA1-Sepharose 4B and detected with the other anti-CD226 mAb, FMU4, in Western blot. There were bands 
because sCD226 could be precipitated by LeoA1-Sepharose 4B and detected with FMU4 in Western blot. One representative 
experiment is shown (n = 3).Page 6 of 8
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IgG-Sepharose 4B (negative control for immunoprecipita-
tion) at 4°C overnight. After 4 times washing (20 min
incubation for each washing) with Washing Buffer (10
mMTris-HCl, 140 mM NaCl, 0.5 mM MgCL2, 0.5 mM
CaCL2, 0.02% NaN3, pH7.4) and following the last cen-
trifugation, the supernatant was aspirated and 40 μl of 2 ×
loading buffer was added to the bead pellet, vortexed,
heated (90–100°C, 5 min), and centrifuged. The superna-
tant was gently collected, without disturbing the pellet,
and then loaded onto 12% SDS-PAGE as the order in Fig-
ure 4, and transferred to one complete nitrocellulose
membrane (Millipore, Massachussets, USA). The mem-
brane was blocked with 5% (w/v) bovine skim milk in
PBS at room temperature for 1 h, then was cut into indi-
vidual lanes using scissors, and incubated with anti-SED
mAb (negative control for Western blot) or anti-CD226
mAb FMU4 [18] at 4°C overnight. Then the membranes
were washes six times with PBS-T and incubated with HRP
labeled goat anti-mouse IgG secondary antibody (DAKO)
at room temperature for 1 h. After four times washes with
PBS-T, the individual membrane lanes were put together
one by one and enhanced chemiluminescence (ECL) rea-
gent (GE Healthcare) was applied to the membranes
according to manufacturer's introductions, which were
then exposed to an x-ray film (Kodak, Rochester, NY,
USA).
Statistical analysis
The Mann-Whitney U test or Kruskal-Wallis test was used
to determine the significance of the differences of sCD226
and mCD226 expression between the groups. And the
paired-samples T test was used to compare percentage of
cytotoxicity between the groups. A P value < 0.05 was
regarded as significant. Analysis was performed with SPSS
(SPSS Inc., Chicago, IL, USA).
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